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Abstract
Introduction
Left untreated, malignant pleural mesothelioma (MPM) is associated with uniformly poor
prognosis. Better survival has been reported with surgery-based multimodality therapy, but
to date, no trial has demonstrated survival benefit of surgery over other therapies. We evalu-
ated whether cancer-directed surgery influenced survival independently from other predic-
tors in a large population-based dataset.
Methods
The SEER database was explored from 1973 to 2009 to identify all cases of pathologically-
proven MPM. Age, sex, race, year of diagnosis, histology stage, cancer-directed surgery,
radiation, and vital status were analyzed. The association between prognostic factors and
survival was estimated using Cox regression and propensity matched analysis.
Results
There were 14,228 patients with pathologic diagnosis of MPM. On multivariable analysis,
female gender, younger age, early stage, and treatment with surgery were independent pre-
dictors of longer survival. In comparison to no treatment, surgery alone was associated with
significant improvement in survival [adjusted hazard ratio (adj HR) 0.64 (0.61–0.67)], but
not radiation [adj HR 1.15 (1.08–1.23)]. Surgery and radiation combined had similar survival
as surgery alone [adj HR 0.69 (0.64–0.76)]. Results were similar when cases diagnosed
between 1973 and 1999 were compared to cases diagnosed between 2000 and 2009.
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Conclusions
Despite developments in surgical and radiation techniques, the prognosis for MPM patients
has not improved over the past 4 decades. Cancer-directed surgery is independently asso-
ciated with better survival, suggesting that multimodal surgery-based therapy can benefit
these patients. Further research in adjuvant treatment is necessary to improve prognosis in
this challenging disease.
Introduction
Mesothelioma is a rare but deadly cancer that has been linked to occupational and environ-
mental asbestos exposure. The incidence of mesothelioma has increased greatly starting from
the seventies, when the effects of past exposure to asbestos became evident, and still shows no
signs of decline in the US, despite the fact that asbestos use has been banned several decades
ago [1]. The diagnosis of mesothelioma often occurs when the disease is already at an advanced
stage, and life expectancy is usually limited to few months. In recent years, several therapeutic
approaches have been attempted with the hope to extend survival, including surgery, radiation,
surgery combined with radiation, chemotherapy in various combinations with radiotherapy
and surgery. A recent meta-analysis comparing survival after extra-pleural pneumonectomy
and pleurectomy decortication [2] suggests that less invasive surgical approaches, such as
pleurectomy/decortication are associated with prolonged survival. A randomized controlled
trial conducted in the UK to assess survival, complications, and quality of life after extra-pleu-
ral pneumonectomy [3] suggested that the extensive surgical approach did not offer any sur-
vival advantage over chemotherapy alone.
Despite the many studies published so far, there is no agreement on which is the optimal
therapeutic strategy that would obtain the longest survival of mesothelioma patients. Because
mesothelioma is a rare disease, single institutions rarely collect a large enough number of cases
to conduct outcome studies on the effects of the various therapeutic modalities. The Surveil-
lance, Epidemiology and End Results (SEER) data base includes a large population based sam-
ple of unselected cancer patients for which information on tumor characteristics at diagnosis,
type of therapy and outcome is available. We have analyzed the mesothelioma cases present
within SEER, to study the effect of therapy and other prognostic factors on survival.
Methods
The SEER database was explored from 1973 to 2009, and all cases identified as mesothelioma
within the site recode ICD-O-3 variable by ICD-O-3 morphology were extracted. Only patients
with pathologically proven malignant mesothelioma of pleura and lung were included. Exclu-
sion criteria included age below 18 years old, all postmortem cases, non-microscopically con-
firmed cases (for which no pathology confirmation of the diagnosis was available), and any
case without survival time in the database (n = 1,077). Malignant mesothelioma of other sites
(retroperitoneal, peritoneal, genital, heart, mediastinum, soft tissue, digestive, other, and
unknown primary site) were also excluded.
The SEER 09 registry included cases from Atlanta, Connecticut, Detroit, Hawaii, Iowa, New
Mexico, San Francisco-Oakland, Seattle-Puget Sound, and Utah from 1973–2004. The SEER
13 registry included cases from Los Angeles, San Jose-Monterrey, rural Georgia, and Alaska in
addition to SEER 09 cases. The SEER 17 registry included cases from Greater California, Ken-
tucky, Louisiana, and New Jersey from 2000 to 2004. The SEER 18 registry included cases from
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Greater Georgia from 2000 and on, with the exception of adjustments for the areas impacted
by Hurricanes Katrina and Rita. SEER is a publicly available resource containing anonymous
information, and as such data extracted from SEER was deemed “non-human study” by the
North Shore LIJ IRB committee.
Definition of Staging
Localized: Invasive tumor confined to pleura; ipsilateral parietal and/or visceral pleura; meso-
thelioma with nodules beneath the visceral pleural surface; and localized, not otherwise speci-
fied. Regional: Extension to adjacent organs/structure: adjacent connective tissue, pericardium,
endothoracic fascia, diaphragm; mesothelioma nodules that have broken through the visceral
pleural surface to the lung surface, lung involvement not otherwise specified; extension to adja-
cent organs such as the chest wall, ribs, heart muscle, mediastinal organs and tissues; mesothe-
lioma with malignant pleural fluid/effusion; regional ipsilateral lymph nodes; and regional not
otherwise specified.
Distant: Contralateral pleura and lung, extension to intraabdominal organs, cervical tissues,
peritoneum, metastasis; further contiguous extension; unknown if extension or metastasis; and
distant lymph nodes.
Definition of Cancer-directed surgery
For cases diagnosed after 1998, they were identified as having received cancer-directed surgery
if given any of the following codes for the “Rx Summ-Surg Prim Site” variable: 30 = simple/par-
tial surgical removal of primary site; 40 = total surgical removal of primary site, enucleation;
50 = “debulking”; 60 = radical surgery which included partial or total removal of the primary
site with a resection in the continuity (partial or total removal) with other organs.
For cases prior to 1998, cases were identified as having received cancer-directed surgery if
given any of the following codes for the “Site Specific Surgery” variable: (10 = Local surgical
excision or destruction of lesion; 20 = Partial/wedge/segmental resection; 30, 40 = Lobectomy/
bilobectomy with/without dissection of lymph nodes; 50 = Complete/total/standard pneumo-
nectomy, pneumonectomy, NOS; 60 = Radical pneumonectomy plus dissection of mediastinal
lymph nodes; 70 = Extended radical pneumonectomy with diaphragm plus lymph nodes;
90 = Resection of lung, NOS; surgery, NOS.
For all cases, the code 00 (which indicated “no surgical procedure had been performed”)
and the codes for other types of surgery (codes 01 = Incisional, needle, or aspiration biopsy of
other than primary site; 02 = Incisional, needle, or aspiration biopsy of primary site; 03 = Ex-
ploratory only (no biopsy); 04 = Bypass surgery, -ostomy only (no biopsy); 05 = Exploratory
only and incisional, needle or aspiration biopsy of primary site or other sites) were used to cate-
gorize patients who did not undergo cancer-directed surgery.
Statistical analysis
Variables analyzed include age at diagnosis, sex, race, year of diagnosis, vital status, stage, sur-
gery, and radiation. Overall survival was defined as the time between the initial diagnosis date
and either date of death or last follow-up. Univariate analyses of survival in relation to patient’s
demographics and tumor characteristics were conducted by the Ederer II method. The inde-
pendent contribution to survival of several prognostic factors was analyzed with multivariate
regression methods based on the Cox proportional hazards model. A propensity analysis for
the association of surgery with survival, matched on sex, age, and stage was also conducted. All
analyses were performed using SAS version 9.2 (Cary, NC, USA).
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Results
There were over 14,000 cases of malignant pleural mesothelioma (MPM) in the SEER data set.
A description of the population is reported in Table 1. The majority of the patients were white,
and roughly three quarters of the cases were males; median age at diagnosis was 62 years. More
than half of the cases were diagnosed with distant metastases. Only 23% of the cases received
cancer-directed surgery, and 13% received radiation therapy. Localized cases are more likely to
be treated with radiation only, while regional cases with surgery only or in combination with
chemotherapy. Distant cases are less likely to receive surgery or radiotherapy; probably other
palliative care is used, which is not collected by SEER. The median overall survival was 7
months,; the large part of the patients (91%) was deceased at the end of follow-up.
Predictors of survival: at univariate analysis, survival was longer at younger ages, in females,
in cases that were diagnosed at early stages, in patients treated with surgery or a combination
of surgery and radiation (Fig 1). At multivariate analysis (Table 2), independent significant pre-
dictors of survival were: being female [adjusted Hazard Ratio (adjHR): 0.79 (95% CI: 0.75–
0.82)], disease stage [adjHR for distant versus local disease: 1.4 (95% CI: 1.31–1.49)], and age
[adjHR: 1.02 (95% CI: 1.02–1.02) with increasing age]. Survival was also improved in the most
recent calendar year of diagnosis (adjHR: 0.81 (95%CI: 0.77–0.86) for patients diagnosed in
2005–2009 versus patients diagnosed in 1973–1989). Epithelial histology was associated with
best survival in comparison to the other histologic types.
In comparison to no surgery/radiation treatment, surgery alone was associated with signifi-
cant improvement in survival [adj HR 0.64 (95% CI: 0.61–0.67)], while radiation did not
improve survival [adj HR 1.15 (95% CI: 1.08–1.23)]. Surgery and radiation combined was asso-
ciated with similar survival as surgery alone [adj HR 0.69 (95% CI: 0.64–0.76)]. The median
survival of the group not receiving radiotherapy or surgery was 6.5 months, very similar to the
median survival of the group treated with radiotherapy (7.5 months), while median survival in
the surgical group was 14.5 months, and in those receiving both radiation and surgery was 13
months. A stratified analysis according to calendar year of diagnosis shows that cases diag-
nosed earlier on are also experiencing worse survival than cases diagnosed in more recent
times (Table 3). In patients diagnosed between 1973 and 1999, the adj HR for radiation was
1.14 (95% CI: 1.05–1.23), for surgery 0.63 (95% CI: 0.59–0.68), for surgery plus radiation 0.75
(95% CI: 0.66–0.84); similar results were obtained in patients diagnosed between 2000 and
2009.
To confirm that the relative advantage of surgery on survival is not due to differences in
patient characteristics among those who received surgery compared to other treatment catego-
ries, a propensity score analysis was conducted where patients were propensity balanced based
on sex, stage, and age using the nearest neighbor method. The effect of surgery on survival in
the raw data set and after adjustment using the propensity score method was not significantly
different from one another (HR = 0.64; 95% CI 0.61–0.67 and matched HR = 0.68; 95% CI
0.66–0.72 respectively).
Discussion
The present analysis of a large population based cancer data set suggests that cancer-directed
surgery is independently associated with better survival, alone or in combination with radio-
therapy, suggesting that multimodal surgery-based therapy can benefit MPM patients. The
median survival of the group treated with surgery was double the value observed in those not
receiving radiotherapy or surgery, or among those treated with radiotherapy. These differences
are meaningful in a disease that has a very quick evolution and extremely short survival rate,
and are very similar to what reported by others [4]. One aspect that needs to be considered is
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Table 1. Patient, Disease, and Treatment Characteristics (n = 14228), SEER (Surveillance, Epidemiol-
ogy, and End Results).
Variable Categories Total
Registry SEER 9 7994 (56%)
SEER 13 (> 1992) 1623 (11%)
SEER 17 (>2000) 4227 (30%)
SEER 18 384 (3%)
Sex Male 11032 (78%)
Female 3196 (22%)
Race White 13046 (92%)
Black 688 (5%)
Other 494 (3%)
Age (yr) 18–49 910 (6%)
50–59 1795 (13%)
60–69 3421 (24%)
70–79 4875 (34%)
80+ 3227 (23%)
Diagnosis year 1973–1989 2695 (19%)
1990–1994 1514 (11%)
1995–1999 1764 (12%)
2000–2004 4048 (28%)
2005–2009 4207 (30%)
Overall Stage Localized 1572 (11%)
Regional 2355 (16%)
Distant 8367 (59%)
Unknown 1934 (14%)
Histology Fibrous 1096 (8%)
Epithelial 3292 (23%)
Biphasic 650 (4%)
Mesothelioma, NOS 9190 (65%)
Cancer-directed surgery No 10921 (77%)
Yes 3307 (23%)
Type of cancer-directed surgery Partial resection 542 (16.3%)
Lobectomy 1232 (37.3%)
Pneumonectomy 808 (24.5%)
Resection NOS 725 (21.9%)
Radiation No 12050 (85%)
Yes 1805 (13%)
Unknown 373 (2%)
Vital Status Alive 1326 (9%)
Dead 12902 (91%)
Survival in months Median 7
1973–1989 8
1990–1994 7
1995–1999 7
2000–2004 7
2005–2009 6
doi:10.1371/journal.pone.0145039.t001
Determinants of Mesothelioma Survival
PLOS ONE | DOI:10.1371/journal.pone.0145039 December 14, 2015 5 / 8
that the SEER program includes data from both general hospitals and highly specialized cancer
centers, and the surgical techniques used may greatly differ between these two hospital settings.
centers. However, the improved survival with multi-modal therapy reported here confirms
results of individual studies conducted in Europe [4] or in the US [5] on smaller series. Bovo-
lato et al showed a statistically significant improvement in patients who underwent a surgical
approach versus those who were non-surgically treated [4]. Kapeles et al [5]suggests that
patients treated with trimodality therapy have a significantly improved survival, but the result
is not confirmed by others [6]. The Kapeles study however does not disentangle the effects of
each individual procedure (surgery versus radiation versus chemotherapy); other predictors of
survival were gender and age, similar to what we report here.
Radiation for MPM has been shown to be effective in trials conducted at specialized centers
[7] suggesting that such approach should be conducted by experts in the field. Results from our
study indicate that surgery is the main determinant of survival, alone or in combination with
radiation.
The present study follows a previously published SEER analysis from our group [8] on a
smaller sample of patients (n = 5937), on the predictors of undergoing surgery. The study found
that age, race and stage were main factors associated with the surgical approach, and provided
the first evidence that surgery was associated with improved survival. However, the paper did not
compare survival according to the different treatment approaches as we have done here.
The results we present have several limitations: patients are usually selected for surgery
according to a combination of clinical factors such performance status, pulmonary and
cardiac function, and comorbid conditions, which are not recorded in the SEER data base,
and could contribute to survival. Therefore, although we conducted a propensity analysis tak-
ing into account age, sex and stage, we could not consider other important factors such as
comorbidities.
Fig 1. Survival according to type of treatment (SEER database).
doi:10.1371/journal.pone.0145039.g001
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Another limitation is that the SEER data base does not record whether patients were treated
with curative-intent versus palliative-intent, nor if patients received chemotherapy, what che-
motherapeutic agents were used and in what dosage or scheme. The contribution of chemo-
therapy alone on MPM survival seems to be modest: a recent review of the published
randomized clinical trials comparing medical treatment shows that only 10 RCT were con-
ducted comparing two chemo-therapy regimens, and only the 2 involving platinum-based
compounds showed a statistically significant improvement in survival, in the order of 2–3
months difference [9]. A previously published study [4] suggests that MPM surgical approach
improves survival over non-surgical approach (including radiation and chemotherapy).
Another limitation of the large SEER data base is that radiotherapy details are not well-doc-
umented, for example the radiation dose or radiation fields cannot be determined. Another
missing information is the sequence of the various therapeutic approaches.
Table 2. Association between Patient and Disease Characteristics and Survival.
Variable Category Adjusted HR (95% CI) *
Sex Male 1 (Ref)
Female 0.79 (0.75–0.82)
Race White 1 (ref)
Black 1.07 (0.98–1.16)
Other 0.98 (0.89–1.08)
Age (years) continuous 1.02 (1.02–1.02)
Stage Localized 1 (ref)
Regional 1.35 (1.25–1.44)
Distant 1.40 (1.31–1.49)
Histology Epithelial 1 (ref)
Fibrous 1.54 (1.43–1.66)
Biphasic 1.46 (1.33–1.60)
Meso NOS 1.18 (1.13–1.24)
Diagnosis year 1973–1989 1 (ref)
1990–1994 0.92 (0.86–0.98)
1995–1999 0.88 (0.82–0.93)
2000–2004 0.87 (0.83–0.92)
2005–2009 0.81 (0.77–0.86)
Therapy No radiation or surgery 1 (ref)
Radiation only 1.15 (1.08–1.23)
Surgery only 0.64 (0.61–0.67)
Radiation and surgery 0.69 (0.64–0.76)
*Adjusted for all other variables in the table
doi:10.1371/journal.pone.0145039.t002
Table 3. Effect of therapy on survival according to period of diagnosis.
Adjusted HR (95% CI) *
Therapy 1973–1999 2000–2009
No radiation or surgery 1 (Ref) 1 (Ref)
Radiation only 1.14 (1.05–1.23) 1.26 (1.14–1.41)
Surgery only 0.63 (0.59–0.68) 0.68 (0.64–0.73)
Radiation and surgery 0.75 (0.66–0.84) 0.65 (0.57–0.73)
*Adjusted for sex, race, age, and stage
doi:10.1371/journal.pone.0145039.t003
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However, this collection of MPM is one of the largest published in the literature, and is
informative for additional observational and experimental studies comparing treatment strate-
gies for MPM. Despite developments in surgical and radiation techniques, the prognosis for
pleural mesothelioma patients has not improved over the past 4 decades. A possible exception
is represented by BAP1 mutated MPM patients [10]. In these patients, MPM seems to progress
very slowly and surgery might be particularly indicated as main treatment. Further research on
the impact of adjuvant treatment, and of new approaches such as gene therapy and immuno-
therapy, alone or in combination with surgery, is necessary to improve prognosis in this chal-
lenging disease [11].
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